Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Michael Dwinell
Medical College of Wisconsin, Department: Biochemistry
Should you be removed from our database? Contact us at [email protected]. Read more below.
Protein Foundry, LLC
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
See uploaded document in Section 3.
Structural Basis for Chemokine Function
Five-year survival rates for pancreatic cancer are below 15%, and only 1 in 6 patients are surgical candidates. CXCL12 is a pro-metastatic protein, called a chemokine that uses the CXCR4 receptor to draw pancreatic cancer cells away from the primary tumor. Chemokines and their cell- surface receptors form a network of signaling proteins that orchestrates the homing and migration of white blood cells, stem cells and metastatic cancer cells to specific organs and tissues throughout the human body. To develop new therapeutic molecules that block cancer progression, enhance wound healing, or prevent chronic inflammation, the molecular details of chemokine specificity and receptor signaling must be understood. In the last funding period, we discovered that linking two CXCL12 molecules together (to create a CXCL12 'locked dimer') converts this chemokine into a potent inhibitor of metastasis. In this project, we propose to define the molecular basis for chemokine selectivity and translate our patented inhibitor molecule into a new therapeutic strategy for pancreatic cancer.
Filed on November 03, 2016.
Tell us what you know about Michael Dwinell's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.